Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 90

1.

Comparative oncology: The paradigmatic example of canine and human mast cell neoplasms.

Willmann M, Hadzijusufovic E, Hermine O, Dacasto M, Marconato L, Bauer K, Peter B, Gamperl S, Eisenwort G, Jensen-Jarolim E, Müller M, Arock M, Vail DM, Valent P.

Vet Comp Oncol. 2019 Mar;17(1):1-10. doi: 10.1111/vco.12440. Epub 2018 Sep 24. Review.

2.

"Masitinib" is safe and effective for the treatment of canine mast cell tumors.

Gentilini F.

J Vet Intern Med. 2010 Jan-Feb;24(1):6; author reply 7. No abstract available.

3.

The novel HSP90 inhibitor STA-9090 exhibits activity against Kit-dependent and -independent malignant mast cell tumors.

Lin TY, Bear M, Du Z, Foley KP, Ying W, Barsoum J, London C.

Exp Hematol. 2008 Oct;36(10):1266-77. doi: 10.1016/j.exphem.2008.05.001. Epub 2008 Jul 26.

4.

NI-1: a novel canine mastocytoma model for studying drug resistance and IgER-dependent mast cell activation.

Hadzijusufovic E, Peter B, Herrmann H, Rülicke T, Cerny-Reiterer S, Schuch K, Kenner L, Thaiwong T, Yuzbasiyan-Gurkan V, Pickl WF, Willmann M, Valent P.

Allergy. 2012 Jul;67(7):858-68. doi: 10.1111/j.1398-9995.2012.02833.x. Epub 2012 May 15. Erratum in: Allergy. 2018 Nov;73(11):2264.

5.

Calcitriol (1,25-dihydroxycholecalciferol) enhances mast cell tumour chemotherapy and receptor tyrosine kinase inhibitor activity in vitro and has single-agent activity against spontaneously occurring canine mast cell tumours.

Malone EK, Rassnick KM, Wakshlag JJ, Russell DS, Al-Sarraf R, Ruslander DM, Johnson CS, Trump DL.

Vet Comp Oncol. 2010 Sep;8(3):209-20. doi: 10.1111/j.1476-5829.2010.00223.x.

PMID:
20691028
6.

The JAK2/STAT5 signaling pathway as a potential therapeutic target in canine mastocytoma.

Keller A, Wingelhofer B, Peter B, Bauer K, Berger D, Gamperl S, Reifinger M, Cerny-Reiterer S, Moriggl R, Willmann M, Valent P, Hadzijusufovic E.

Vet Comp Oncol. 2018 Mar;16(1):55-68. doi: 10.1111/vco.12311. Epub 2017 Apr 11. Erratum in: Vet Comp Oncol. 2019 Sep;17(3):446-447.

7.

Synergistic antiproliferative effects of KIT tyrosine kinase inhibitors on neoplastic canine mast cells.

Gleixner KV, Rebuzzi L, Mayerhofer M, Gruze A, Hadzijusufovic E, Sonneck K, Vales A, Kneidinger M, Samorapoompichit P, Thaiwong T, Pickl WF, Yuzbasiyan-Gurkan V, Sillaber C, Willmann M, Valent P.

Exp Hematol. 2007 Oct;35(10):1510-21. Epub 2007 Aug 2.

PMID:
17681669
8.

A retrospective review of treatment and response of high-risk mast cell tumours in dogs.

Miller RL, Van Lelyveld S, Warland J, Dobson JM, Foale RD.

Vet Comp Oncol. 2016 Dec;14(4):361-370. doi: 10.1111/vco.12116. Epub 2014 Sep 15.

PMID:
25223579
9.

Combination CCNU and vinblastine chemotherapy for canine mast cell tumours: 57 cases.

Cooper M, Tsai X, Bennett P.

Vet Comp Oncol. 2009 Sep;7(3):196-206. doi: 10.1111/j.1476-5829.2009.00190.x.

PMID:
19691648
10.

Masitinib is safe and effective for the treatment of canine mast cell tumors.

Hahn KA, Ogilvie G, Rusk T, Devauchelle P, Leblanc A, Legendre A, Powers B, Leventhal PS, Kinet JP, Palmerini F, Dubreuil P, Moussy A, Hermine O.

J Vet Intern Med. 2008 Nov-Dec;22(6):1301-9. doi: 10.1111/j.1939-1676.2008.0190.x. Epub 2008 Sep 24. Erratum in: J Vet Intern Med. 2009 Jan-Feb;23(1):224. Oglivie, G [corrected to Ogilvie, G].

11.

Expression of c-kit proto-oncogene in canine mastocytoma: a kinetic study using real-time polymerase chain reaction.

Turin L, Acocella F, Stefanello D, Oseliero A, Fondrini D, Brizzola S, Riva F.

J Vet Diagn Invest. 2006 Jul;18(4):343-9.

PMID:
16921872
12.

Ex vivo evaluation of imatinib mesylate for induction of cell death on canine neoplastic mast cells with mutations in c-Kit exon 11 via apoptosis.

Rossi G, Bertani C, Mari S, Marini C, Renzoni G, Ogilvie G, Magi GE.

Vet Res Commun. 2013 Jun;37(2):101-8. doi: 10.1007/s11259-013-9550-5. Epub 2013 Jan 13.

PMID:
23315207
13.

Vinblastine and prednisolone as adjunctive therapy for canine cutaneous mast cell tumors.

Davies DR, Wyatt KM, Jardine JE, Robertson ID, Irwin PJ.

J Am Anim Hosp Assoc. 2004 Mar-Apr;40(2):124-30.

PMID:
15007048
14.

Is lymph node metastasis of canine grade 2 MCTs justification for adjuvant therapy?

Schulman FY.

Vet Comp Oncol. 2015 Jun;13(2):151. doi: 10.1111/vco.12126. No abstract available.

PMID:
25968074
15.

Heterogeneity of internal tandem duplications in the c-kit of dogs with multiple mast cell tumours.

Amagai Y, Tanaka A, Matsuda A, Jung K, Oida K, Nishikawa S, Jang H, Matsuda H.

J Small Anim Pract. 2013 Jul;54(7):377-80. doi: 10.1111/jsap.12069. Epub 2013 Apr 25.

PMID:
23614673
16.

IL-4 downregulates expression of the target receptor CD30 in neoplastic canine mast cells.

Bauer K, Hadzijusufovic E, Cerny-Reiterer S, Hoermann G, Reifinger M, Pirker A, Valent P, Willmann M.

Vet Comp Oncol. 2017 Dec;15(4):1240-1256. doi: 10.1111/vco.12260. Epub 2016 Aug 9.

17.

Targeting of heat-shock protein 32/heme oxygenase-1 in canine mastocytoma cells is associated with reduced growth and induction of apoptosis.

Hadzijusufovic E, Rebuzzi L, Gleixner KV, Ferenc V, Peter B, Kondo R, Gruze A, Kneidinger M, Krauth MT, Mayerhofer M, Samorapoompichit P, Greish K, Iyer AK, Pickl WF, Maeda H, Willmann M, Valent P.

Exp Hematol. 2008 Nov;36(11):1461-70. doi: 10.1016/j.exphem.2008.06.002. Epub 2008 Aug 23.

PMID:
18723263
18.

Identification of additional mitochondrial DNA mutations in canine mast cell tumours.

Śmiech A, Ślaska B, Surdyka M, Grzybowska-Szatkowska L, Łopuszyński W, Różańska D.

Acta Vet Scand. 2016 May 4;58(1):28. doi: 10.1186/s13028-016-0210-y.

19.

Canine mast cell tumours: a review of the pathogenesis, clinical features, pathology and treatment.

Welle MM, Bley CR, Howard J, Rüfenacht S.

Vet Dermatol. 2008 Dec;19(6):321-39. doi: 10.1111/j.1365-3164.2008.00694.x. Review.

PMID:
18980632
20.

Canine oral mucosal mast cell tumours.

Elliott JW, Cripps P, Blackwood L, Berlato D, Murphy S, Grant IA.

Vet Comp Oncol. 2016 Mar;14(1):101-11. doi: 10.1111/vco.12071. Epub 2013 Nov 11.

PMID:
24215587

Supplemental Content

Support Center